Grail
GRAL
132.90
-4.38
-3.19%
Grail
US · GRAL
#1873 by market cap
Listed 2024
132.90
-4.38
-3.19%
Live - 5344 symbols - heartbeat 472s ago
· 2026-10-08 07:39
Pre-market
130.98
-1.44%
After-hours
132.70
-0.15%
Overnight
131.00
-1.43%
- Market cap
- 5.94B
- P/E (TTM)i
- -13.72
- P/Bi
- 2.33
- EPSi
- -11.11
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on GRAL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.26, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +17.18% YoY
Margins
- Gross margin
- -42.52%
- Operating margin
- -362.95%
- Net margin
- -277.47%
Key ratios & quality
- Altman Z-Scorei
- 5.26
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | 55.55M | 93.11M | 125.60M | 147.17M |
| Gross profit | -- | -- | -116.45M | -95.61M | -78.02M | -62.57M |
| Selling & admin expenses | 64.34M | 88.58M | 296.44M | 362.56M | 367.82M | 275.80M |
| Research & development | 223.16M | 167.09M | 329.58M | 338.75M | 322.38M | 195.79M |
| Operating profit | -287.50M | -255.66M | -742.46M | -796.92M | -768.22M | -534.16M |
| Pretax profit | -275.23M | -245.05M | -5.44B | -1.51B | -2.16B | -534.50M |
| Tax | 485.00K | -195.00K | -42.29M | -41.95M | -135.36M | -126.15M |
| Net profit | -275.72M | -244.86M | -5.40B | -1.47B | -2.03B | -408.35M |
| Basic EPS | -9 | -8 | -174 | -47 | -64 | -11 |
| Diluted EPS | -8.88 | -7.89 | -173.89 | -47.21 | -63.54 | -11.11 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 31.84M | 35.54M | 36.19M | 43.60M | 40.79M | 44.69M |
| Gross profit | -19.93M | -17.78M | -13.73M | -11.14M | -14.31M | -12.57M |
| Selling & admin expenses | 80.05M | 66.45M | 62.91M | 66.38M | 73.44M | 88.37M |
| Research & development | 53.63M | 46.63M | 48.65M | 46.90M | 48.02M | 47.43M |
| Operating profit | -153.61M | -130.85M | -125.29M | -124.41M | -135.77M | -148.36M |
| Pretax profit | -146.41M | -152.86M | -118.72M | -116.52M | -127.52M | -166.71M |
| Tax | -40.20M | -38.87M | -29.74M | -17.34M | -34.34M | -56.46M |
| Net profit | -106.21M | -113.99M | -88.98M | -99.18M | -93.19M | -110.25M |
| Basic EPS | -3 | -3 | -2 | -2 | -2 | -3 |
| Diluted EPS | -3.10 | -3.18 | -2.46 | -2.44 | -2.29 | -2.56 |
Balance sheet
| Line item | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 649.23M | 557.51M | 295.63M | 156.07M | 819.86M | 953.85M |
| Cash & ST investments | 641.35M | 544.34M | 241.60M | 97.29M | 763.47M | 904.43M |
| Inventory | -- | -- | 19.76M | 21.70M | 18.63M | 16.02M |
| Total assets | 686.85M | 635.52M | 4.94B | 3.91B | 2.98B | 2.92B |
| Total current liabilities | 74.16M | 44.93M | 134.94M | 163.61M | 76.93M | 79.67M |
| Short-term debt | -- | 4.60M | 13.34M | 14.81M | 13.26M | 11.72M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,689,697,000.00 | 1,848,052,000.00 | 291,825,000.00 | 267,627,000.00 | 479,902,000.00 | 344,153,000.00 |
| Total equity | -1.00B | -1.21B | 4.65B | 3.65B | 2.50B | 2.58B |
| Retained earnings | -1.06B | -1.31B | -- | -- | -9.80B | -10.21B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 727.66M | 651.84M | 589.38M | 953.85M | 877.35M | 914.72M |
| Cash & ST investments | 674.58M | 602.75M | 540.13M | 904.43M | 823.11M | 861.61M |
| Inventory | 18.72M | 19.74M | 18.39M | 16.02M | 17.19M | 17.76M |
| Total assets | 2.85B | 2.70B | 2.60B | 2.92B | 2.80B | 2.84B |
| Total current liabilities | 74.98M | 70.64M | 77.43M | 79.67M | 74.71M | 83.54M |
| Short-term debt | 12.97M | 13.69M | 14.02M | 11.72M | 9.94M | 10.70M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 433,937,000.00 | 387,908,000.00 | 361,068,000.00 | 344,153,000.00 | 302,788,000.00 | 301,032,000.00 |
| Total equity | 2.41B | 2.31B | 2.24B | 2.58B | 2.50B | 2.54B |
| Retained earnings | -9.91B | -10.02B | -10.11B | -10.21B | -10.30B | -10.42B |
Cash flow
| Line item | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -209.26M | -245.79M | -561.31M | -595.80M | -577.16M | -299.01M |
| Depreciation & amortization | 14.08M | 10.31M | 154.76M | 158.70M | 158.06M | 156.34M |
| Free cash flow | -225.25M | -249.13M | -584.17M | -608.69M | -582.36M | -299.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | 0 | 418.80M |
| Ending cash balance | 96.72M | 144.42M | 246.13M | 101.51M | 217.58M | 256.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -95.01M | -76.97M | -63.25M | -63.79M | -86.99M | -80.73M |
| Depreciation & amortization | 39.28M | 39.18M | 38.98M | 38.91M | 38.79M | 38.69M |
| Free cash flow | -95.07M | -77.33M | -63.63M | -63.88M | -87.49M | -81.16M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 137.24M | 130.78M | 133.87M | 256.70M | 76.32M | 62.62M |
Returns & efficiency
| Line item | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -116.21 | -30.96 | -65.92 | -16.07 |
| ROA %i | -40.14 | -37.03 | -109.34 | -29.00 | -58.78 | -13.83 |
| ROIC %i | -- | -- | -113.89 | -30.46 | -65.12 | -16.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -1,336.56 | -855.93 | -611.67 | -362.95 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.75 | 12.41 | 2.19 | 0.95 | 10.66 | 11.97 |
| Quick ratioi | 8.67 | 12.13 | 1.94 | 0.74 | 10.19 | 11.58 |
| Debt / assetsi | 0.12 | 6.49 | 1.94 | 2.16 | 2.28 | 1.88 |
| LT debt / equityi | -- | -- | 1.78 | 1.91 | 2.19 | 1.67 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | 38.37 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -59.78 | -17.68 | -16.83 | -16.07 | -16.09 | -16.12 |
| ROA %i | -50.41 | -14.83 | -14.21 | -13.83 | -13.99 | -14.12 |
| ROIC %i | -59.35 | -18.23 | -17.29 | -16.53 | -16.60 | -16.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -531.25 | -450.46 | -385.46 | -362.95 | -330.72 | -323.02 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.71 | 9.23 | 7.61 | 11.97 | 11.74 | 10.95 |
| Quick ratioi | 9.26 | 8.76 | 7.19 | 11.58 | 11.29 | 10.55 |
| Debt / assetsi | 2.26 | 2.30 | 2.25 | 1.88 | 1.82 | 3.21 |
| LT debt / equityi | 2.13 | 2.09 | 1.99 | 1.67 | 1.64 | 3.17 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Multi-cancer early detection testing and services100.00%
Region
United States93.15%
International6.85%
Quote time 2026-10-08 07:39:10 · For reference only, not investment advice and not tailored to your situation.